Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Kaida Bio Pharma announced it raised $1.57 Million in an initial filing from an offering of $3 Million
PRIVATEJan 21, 2026•7 months ago
Amount Raised
$1.57 Million
Round Type
Seed
Fort LauderdaleBiotechnology
Company Information
Company
Kaida BioPharma
Location
416 SW 1st Avenue
Fort Lauderdale, Florida, United States
About
Kaida BioPharma was founded on the research principles and clinical evidence of G129R, a growth hormone antagonist that has shown to induce programmed cell death (autophagy) in gynecologic tumors. Our collaboration with Dr. John Langenheim, professor at Thomas Jefferson University and Dr. Anil Sood at MD Anderson, who have published extensive research on G129R, has provided solutions we intend to bring to the clinic. At Kaida, we are dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. Our mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference.
Don't miss Kaida BioPharma's next move
Get an email the moment Kaida BioPharma raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Predictive Intelligence
Strategic
ML-powered predictions for Kaida BioPharma's next move
Fort LauderdaleBiotechnology